CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder

Positive
AI Analysis

Summary

OMass Therapeutics raised $310M in a major private financing round to develop treatments for genetic adrenal disorders, competing with Neurocrine and Vertex-backed Crinetics in the endocrinology space.

Importance:6/10
Sentiment:
0.70
private_financingendocrinologygenetic_adrenal_disorderUK_biotechrare_disease
Related Companies

Read the original article

Published by Endpoints News on October 15, 2026 6:00 AM

Read Original